IDEXX Laboratories (IDXX) Peer Comparison
$690.24
As on 17-Nov-2026 16:00EST
Market cap
$55,484 Mln
Revenue (TTM)
$4,662 Mln
P/E Ratio
47.5
P/B Ratio
29.4
Div. Yield
0 %
| IDEXX Laboratories (IDXX) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Danaher (DHR) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
55,484 | 259,154 | 187,950 | 153,768 | 163,332 |
Revenue ($ Mln) |
4,662 | 47,351 | 48,229 | 11,578 | 25,608 |
Net Profit ($ Mln) |
1,182.19 | 7,083.00 | 4,701.00 | 2,957.20 | 4,331.00 |
Net Margin (%) |
25.36 | 14.96 | 9.75 | 25.54 | 16.91 |
RoE (%) |
69.03 | 13.24 | 9.12 | 17.58 | 8.13 |
Price to Earnings |
47.45 | 36.89 | 40.49 | 53.64 | 38.44 |
Price-To-Book |
29.42 | 4.86 | 3.64 | 9.54 | 3.09 |
Income Statement ($ Mln)
| IDEXX Laboratories (IDXX) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Danaher (DHR) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
4,662.22 | 47,351.00 | 48,229.00 | 11,578.00 | 25,608.00 |
|
Cost of Revenue
|
1,737.98 | 27,729.00 | 20,720.00 | 3,798.50 | 10,603.00 |
|
Gross Profit
|
2,659.58 | 18,239.00 | 24,607.00 | 6,642.30 | 14,970.00 |
|
Operating Expenses
|
1,418.13 | 11,106.00 | 20,276.00 | 4,495.40 | 9,787.00 |
|
Operating Profit (EBIT)
|
1,506.11 | 8,515.00 | 7,233.00 | 3,284.10 | 5,218.00 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
1,478.97 | 7,869.00 | 6,562.00 | 3,619.00 | 4,818.00 |
|
Provision for Tax
|
296.78 | 742.00 | 1,861.00 | 645.90 | 487.00 |
|
Profit after Tax (Net Income)
|
1,182.19 | 7,083.00 | 4,701.00 | 2,957.20 | 4,331.00 |
|
Minority Interest
|
0.00 | -22.00 | 0.00 | -15.90 | 0.00 |
|
Consolidated Profit
|
0.00 | 1,964.00 | 1,776.00 | 0.00 | 1,197.00 |
Liabilities ($ Mln)
| IDEXX Laboratories (IDXX) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Danaher (DHR) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1,869.18 | 54,762.00 | 51,027.00 | 15,986.20 | 53,621.00 |
|
Minority Interest
|
0.00 | -22.00 | 0.00 | -15.90 | 0.00 |
|
Non-Current Liabilities
|
573.71 | 45,295.00 | 40,472.00 | 698.30 | 30,610.00 |
|
Current Liabilities
|
1,264.22 | 14,170.00 | 16,152.00 | 2,533.00 | 9,050.00 |
|
Total Liabilities
|
3,350.76 | 110,343.00 | 86,713.00 | 20,458.70 | 83,464.00 |
Assets ($ Mln)
| IDEXX Laboratories (IDXX) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Danaher (DHR) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
2,207.11 | 88,618.00 | 84,751.00 | 10,920.80 | 78,494.00 |
|
Current Assets
|
1,500.00 | 25,615.00 | 23,496.00 | 8,428.30 | 14,787.00 |
|
Total Assets
|
3,350.76 | 110,343.00 | 86,713.00 | 20,458.70 | 83,464.00 |
|
Total Debt*
|
972.96 | 41,370.00 | 31,159.00 | 0.00 | 26,482.00 |
|
Net Current Assets
|
235.78 | 11,445.00 | 7,344.00 | 5,895.30 | 5,737.00 |
Cashflow ($ Mln)
| IDEXX Laboratories (IDXX) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Danaher (DHR) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
1,178.07 | 7,818.00 | 9,566.00 | 3,030.50 | 6,416.00 |
|
Cash Flow from Investing Activities
|
-136.24 | -4,047.00 | -2,422.00 | 665.80 | -1,196.00 |
|
Cash from Financing Activities
|
-1,161.23 | 1,801.00 | -6,309.00 | -2,364.10 | -2,961.00 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| IDEXX Laboratories (IDXX) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Danaher (DHR) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
46.64 | 7.69 | 10.03 | 16.46 | 5.25 |
|
ROE (%)
|
69.03 | 13.24 | 9.12 | 17.58 | 8.13 |
|
ROA (%)
|
24.78 | 5.75 | 4.21 | 13.74 | 4.59 |
|
EBIT Margin (%)
|
32.49 | 18.92 | 15.09 | 33.80 | 20.22 |
|
Net Margin (%)
|
25.36 | 14.96 | 9.75 | 25.54 | 16.91 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| IDEXX Laboratories (IDXX) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Danaher (DHR) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
11.87 | 8.27 | 10.00 | 20.45 | 5.52 |
|
EBIT Growth (%)
|
15.49 | 4.98 | -15.99 | 23.61 | 16.46 |
|
Net Profit Growth (%)
|
15.06 | 7.81 | -66.37 | 7.66 | 23.64 |
|
EPS Growth (%)
|
16.96 | 9.68 | -66.31 | 9.30 | 26.16 |
|
Book Value Growth (%)
|
22.19 | 9.36 | 0.78 | -2.83 | 6.02 |
Valuation Ratios
| IDEXX Laboratories (IDXX) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Danaher (DHR) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
51.52 | 32.43 | 33.55 | 71.47 | 45.04 |
|
Price / Book Value
|
34.00 | 4.09 | 4.20 | 11.45 | 3.10 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
36.80 | 21.61 | 18.87 | 49.76 | 25.42 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| IDEXX Laboratories (IDXX) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Danaher (DHR) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.16 | 0.71 | 0.58 | 0.00 | 0.45 |
|
Short term debt to equity ratio
|
0.31 | 0.04 | 0.03 | 0.00 | 0.04 |
|
Current Ratio
|
1.19 | 1.81 | 1.45 | 3.33 | 1.63 |
|
Quick Ratio
|
0.88 | 1.41 | 1.00 | 2.49 | 1.29 |
|
Interest Coverage
|
42.20 | 6.12 | 7.96 | -- | 14.38 |
Operating Efficiency Ratios
| IDEXX Laboratories (IDXX) | Thermo Fisher Scientific (TMO) | Abbott Laboratories (ABT) | Intuitive Surgical (ISRG) | Danaher (DHR) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
13.21 | 20.33 | 18.73 | 14.87 | 20.02 |
|
Asset Turnover
|
0.98 | 0.38 | 0.43 | 0.54 | 0.27 |
|
Receivable days
|
49.51 | 82.76 | 61.20 | 54.16 | 61.72 |
|
Inventory Days
|
84.38 | 72.19 | 117.44 | 177.54 | 91.69 |
|
Payable days
|
24.95 | 46.50 | 78.11 | 23.93 | 68.44 |
|
Cash Conversion Cycle
|
108.94 | 108.45 | 100.53 | 207.78 | 84.97 |